It appears JavaScript is disabled. In order for this website to function correctly you need to enable JavaScript in your browser.

Back to safety notices

PRAC meeting highlights 8-11 April 2024

08/04/2024

Medicines for human use Pharmacovigilance risk assessment committee (PRAC)

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.

The current PRAC highlights from the April 2024 meeting provides further information on GLP-1 receptor agonists and available evidence not supporting a link with suicidal and self-injurious thoughts and actions.